Posted On: 09/22/2016 10:57:02 AM
Post# of 98185
$RGBP "Because HemaXellerate is a personalized cell therapy product aimed at addressing an unmet medical need, we are hopeful that the FDA will grant it orphan status," said David Koos, Ph.D., Chairman and CEO of Regen BioPharma.
https://finance.yahoo.com/news/regen-biopharm...00009.html
https://finance.yahoo.com/news/regen-biopharm...00009.html
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼
